Titre
Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Cubo, E.
Auteure/Auteur
González, M.
Auteure/Auteur
del Puerto, I.
Auteure/Auteur
de Yébenes, J.G.
Auteure/Auteur
Arconada, O.F.
Auteure/Auteur
Gabriel y Galán, J.M.
Auteure/Auteur
Contributrices/contributeurs
Zangerl, A.
Seppi, K.
Wenning, G.
Poewe, W.
Foeldy, D.
Auff, E.
Schober, T.
Wenzel, K.
Ott, E.
Walli, J.
Leblhuber, F.
Dürr, A.
Bloch, F.
Messouak, O.
Tallaksen, C.
Dubois, B.
Guillamo, JS.
Bachoud-Lévi, AC.
Engles, A.
Krystkowiak, P.
Destée, A.
Memin, A.
Thibaut-Tanchou, S.
Pasquier, F.
Azulay, JP.
Demonet, JF.
Galitzky, M.
Rascol, O.
Mollion, H.
Broussolle, E.
Madigand, M.
Lallement, F.
Goizet, C.
Tison, F.
Arguillère, S.
Viallet, F.
Bakchine, S.
Khoris, J.
Pages, M.
Camu, W.
Resch, F.
Hannequin, D.
Durif, F.
Saudeau, D.
Autret, A.
Andrich, J.
Saft, C.
Kraus, PH.
Przuntek, H.
Ecker, D.
Kramer, B.
Landwehrmeyer, GB.
Ludolph, AC.
Priller, J.
Meierkord, H.
Kuznik, D.
Dose, M.
Squitieri, F.
Albanese, A.
Abbruzzese, G.
Filla, A.
van de Warrenburg, B.
de Jong, D.
Kremer, H.
van Vugt, J.
Grimbergen, Y.
Roos, R.
Gawel, M.
Janik, P.
Kowalczys, H.
Pilczuk, B.
Kwiecinski, H.
Świat, M.
Ochudło, S.
Modestowicz, R.
Niezgoda, A.
łukasik, M.
Lukasik, M.
de Yébenes JG.,
García-Ruiz, P.
Descals£££A Martínez£££ AM.,
Rojo, A.
Fontán, A.
Hernández, J.
Cantarero, S.
Fanjul, S.
Alegre, J.
Roldán, SG.
Mateo, D.
Burguera, JA.
Solis, P.
Calopa, M.
Jaumà, S.
Bas, J.
Tolosa, E.
Muñoz, JE.
Gámez, J.
Cervera, C.
Zarranz, JJ.
Lezcano, E.
Gómez, JC.
Chacón, J.
Dinca, L.
Gamero, MA.
Redondo, L.
Castro, A.
Sesar, A.
López del Val, J.
López, E.
Ríos, C.
Castillio, V.
Burgunder, JM.
Nirkko, A.
Kälin, A.
Vingerhoets, F.
Wider, C.
Groupes de travail
European Huntington's Disease Initiative Study Group
Liens vers les personnes
Liens vers les unités
ISSN
1531-8257
Statut éditorial
Publié
Date de publication
2012
Volume
27
Numéro
3
Première page
439
Dernière page/numéro d’article
442
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
BACKGROUND: Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington's disease.
METHODS: Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's disease (European Huntington's Disease Initiative Study Group). One-hundred and eighty patients were evaluated using the Unified Huntington Disease Rating Scale over 36 months. A placebo effect was defined as an improvement of at least 50% over baseline scores in the Unified Huntington Disease Rating Scale, and clinically relevant when at least 10% of the population met it.
RESULTS: Only behavior showed a significant placebo effect, and the proportion of the patients with placebo effect ranged from 16% (first visit) to 41% (last visit). Nondepressed patients with better functional status were most likely to be placebo-responders over time.
CONCLUSIONS: In Huntington's disease, behavior seems to be more vulnerable to placebo than overall motor function, cognition, and function
METHODS: Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's disease (European Huntington's Disease Initiative Study Group). One-hundred and eighty patients were evaluated using the Unified Huntington Disease Rating Scale over 36 months. A placebo effect was defined as an improvement of at least 50% over baseline scores in the Unified Huntington Disease Rating Scale, and clinically relevant when at least 10% of the population met it.
RESULTS: Only behavior showed a significant placebo effect, and the proportion of the patients with placebo effect ranged from 16% (first visit) to 41% (last visit). Nondepressed patients with better functional status were most likely to be placebo-responders over time.
CONCLUSIONS: In Huntington's disease, behavior seems to be more vulnerable to placebo than overall motor function, cognition, and function
PID Serval
serval:BIB_1E5328A53063
PMID
Date de création
2013-02-12T15:07:50.774Z
Date de création dans IRIS
2025-05-20T13:25:20Z